In many studies, RAAS blockade by AT1R inhibitors or ACEIs led to reduced liver fibrosis by inhibition of HCSs through suppression of AT1R/TGF-β/Smad and AT1R/TGF-β/MAPK signaling pathways which further decrease the generation of ECM [320–322]. This evidence concerns the gene TGFB1 and Hepatic fibrosis.